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1. Introduction 
Congenital heart disease (CHD), the most common type of birth defect, is an abnormal cardio-
circulatory structure or function present at birth, although the disease is often discovered later 
in life. During prenatal life, the incidence of cardiac defect is higher due to affected fetuses that 
are aborted. CHD stems from an alteration in the embryonic development from a normal 
structure, or a failure of a structure to properly develop beyond an early stage of embryonic 
and fetal development. The non-typical patterns of cardio-circulatory flow owning to an 
anatomical defect may significantly influence the structural and functional development of the 
remainder of the circulatory system. Additionally, postnatal events have a marked impact on 
the clinical presentation of a specific isolated malformation.   
As CHD accounts for the most frequent cause of lethal malformation among infants, CHD is 
also considered a major problem affecting public health worldwide (Bernier et al., 2010). 
Despite the continuing progress in non-surgical and surgical treatments that allow for the 
survival of the majority of patients, some complex heart diseases are still associated with 
substantial morbidity and mortality. According to a report, 45% of infant deaths owing to 
congenital anomalies were caused by CHD in Western Europe. In Latin America, North 
America, Eastern Europe and the South Pacific region (including Japan) this proportion has 
been reported to be 35%, 37%, 42% and 48%, respectively (Botto, 2003). 20% of spontaneous 
abortions and 10% of stillbirths are attributed to CHD (Botto, 2001). CHD causes high 
morbidity and mortality among infants, and affects the quality of life during childhood and 
adulthood, depending on the progression of the disease (Majnener et al., 2008). It also affects 
social interactions and the quality of life for parents of children with CHD. 
While newborns with the cardiac disorder are symptomatic and identified soon after birth, 
many others are not diagnosed until the disease progresses into a severe stage. Data from 
the Northern Region Pediatric Cardiology database suggest around 1 in 4 cases of 
congenital heart disease in the UK are diagnosed later in childhood (Petersen et al., 2003). 
The signs and symptoms of heart disease depend on the type and severity of the disease. 
Children with critical cardiac lesion generally exhibit high morbidity and mortality because 
the risk of morbidity and mortality increases as treatment and diagnosis is delayed. 
The screening process is very important to detect congenital heart malformations. One of the 
major contributors to increased mortality and morbidity is clinical deterioration and heart 
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failure prior to diagnosis and treatment. Early detection of CHD in the fetus or in the 
asymptomatic period immediately after birth will reduce clinical deterioration by instigation 
of appropriate management of the disease. Technical improvements in sonographic systems 
during the past two decades have helped the obstetric sonographers detect congenital heart 
anomalies, especially in experienced hands. A fetal cardiac screening with fetal 
echocardiography allows for early detection of CHD allowing for the option of pregnancy 
termination in cases of complicated defects. In areas where termination of pregnancy is a 
realistic and supported option, a universal sonographic screening of all pregnancies with an 
average reported sensitivity of 35% and a termination rate of 43% following prenatal 
diagnosis, would result in a 15% overall reduction of the prevalence of most severe forms of 
CHD (Germanakis & Sifakis, 2006). The information from 20 registries of congenital 
malformation in 12 European countries demonstrated the overall prenatal detection rate of 
CHD was 25% (Garne et al, 2001).  Echocardiography can be used for screening in live birth 
infants. Newborn echocardiographic screening enables pediatricians to detect abnormal 
cardiac characteristics early and accurately, especially heart diseases without murmur such 
as coarctation of the aorta (Coarc), atrial septal defect (ASD), atrioventricular septal defect 
(AVSD), hypertrophic cardiomyopathy and cardiac tumor. In addition, cardiopulmonary 
information obtained from the echocardiographic examination can be useful for neonatal 
care providers (Wang et al., 2007). 
The echocardiographic screening in developing countries may be difficult due to lack of 
echocardiographic machines and sonographers. Fortunately, most of patients with CHDs 
can be detected by clinical presentations and physical examinations. Approximately 90% of 
patients with CHDs were referred for cardiovascular evaluation with cardiac murmur, 
arrhythmia, cyanosis, palpitation and chest pain. False positives occurred 22.3% of the time 
with innocent (functional) murmur, and non organic chest pain or other non cardiac 
diagnosis (Borzouee & Jannati, 2008). In a Toronto study, 0.28% of the school-age children 
were found to have innocent murmurs (Rose et al., 1964). Currently, infants are screened to 
detect CHD by clinical and physical examination after birth and another examination at 6-8 
weeks. However, this screening program can detect only 50% of congenital defects (Knowles 
et al., 2005).   Thailand has a lack of pediatric doctors and cardiologists, and, therefore, there 
has been training available for qualified nurses and health officers to screen patients for 
CHD using clinical and physical examinations. These screenings are not only for infants, but 
also for school-age children and adults too. Although we detected a lot of false positives 
from innocent murmurs and abnormal clinical presentations, we recognized many 
undiagnosed CHD patients and have found many CHD patients who choose to undergo 
proper treatment (Sayasathid et al., 2009, 2010). Another tool to recognize CHD is pulse 
oximetry. It can detect cyanotic CHD which are not detected by routine examination with 
high specificity (99.8%) and very low false positive rate (2%) although the sensitivity was 
only 63%. Either functional or fractional oxygen saturation was measured by pulse oximetry 
with oxygen saturation below 95% as the cut-off level in most studies (Thangaratinam et al., 
2007). Children who are suspected of having CHD should be referred to a pediatric 
cardiologist for definitive diagnosis, suitable treatment and follow up.  
Nonetheless, the cost-effectiveness remains a concern, especially in developing countries. 
Costs are very different between screening using echocardiography versus clinical 
examination. A cost-effectiveness analysis study for screening 100,000 newborns in the UK 
showed the total program cost £300,000 for clinical examination, £480,000 for pulse oximetry 
and £3.54 million for screening echocardiography. The addition cost per additional timely 
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diagnosis of life-threatening CHD ranges from £4,900 for pulse oximetry to £4.5 million for 
screening echocardiography (Knowles et al., 2005). Hence, the public health officers need to 
consider appropriate methods of CHD detections for their countries. 
Although, there have been many studies to find the etiology of CHD, the cause of most 
CHDs continues to be unknown. Some reports suggested the cause to be a combination 
between genetic and environmental factors. Heart disease symptoms in a child are generally 
simple when compared with an adult, and have widely different pathology and physiology. 
Heart disease in an adult is a disease that often happens later in life (acquired heart disease) 
in the blood vessels (coronary artery disease) and heart valves. In this chapter, we will 
describe the possible causes and risk factors of CHD. 
The first corrective surgery with cardiopulmonary bypass for intra-cardiac malformations 
began at the Mayo Clinic and the University of Minnesota Hospital in the 1950s (Lillehei, 
1956). Through the past half century, the diagnosis and treatment of CHDs have markedly 
improved. The rapid evolution of diagnosis, medical and surgical therapies has reduced the 
morbidity and mortality rate. The surgical mortality has decreased from an average of 15% in 
1990 to an average of 5% in 2000 (Kenny, 2008, as cited in Gibbs et al., 2004). The majority of 
infants with CHD are now expected to survive into adolescence and adulthood. Currently, the 
number of adults diagnosed with CHD exceeds the number of children diagnosed with CHD. 
Hence, the objectives of this chapter are to describe epidemiology and etiology of CHD, 
including preventative guidelines for pregnant mothers. The authors hope this will provide 
essential overview to not only physicians and public health officers but also pregnant 
women, interested readers and societal awareness for the possibility of CHD in newborns. 
We also hope to provide appropriate strategies for managing the problem. This would lead 
to an appropriate health care budget and plan for diseased children in the future. 
Abbreviations 
AR  = aortic regurgitation 
AS  = aortic stenosis 
ASD  = atrial septal defect 
AVSD  = atrioventricular septal defect 
BAV  = bicuspid aortic valve 
CHD  = congenital heart disease 
Coarc  = coarctation of the aorta 
DORV  = double outlet right ventricle 
HLH  = hypoplastic left heart 
HRH  = hypoplastic right heart 
IAA  = interrupted aortic arch 
MR  = mitral regurgitation, (MVP = mitral valve prolapse) 
PA  = pulmonary atresia 
PDA  = patent ductus arteriosus 
PS  = pulmonary stenosis 
SV  = single ventricle 
TA  = tricuspid atresia 
T/PAPVR = total/partial anomalous pulmonary venous return  
TGA  = transposition of great arteries 
TOF  = tetralogy of Fallot 
VSD  = ventricular septal defect 
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2. Epidemiology of congenital heart diseases 
2.1 Incidence rate 
The incidence of CHD refers to the number of newly identified cases, children or adult, 
depending on the degree of defective development of the individuals’ heart, per unit of time 
or population. Incidence demonstrates the rate of disease. The incidence of congenital heart 
defect is difficult to precisely determine, partly because of difficulties in definition. 
However, not all cases of congenital heart disease are diagnosed in infancy. Incidence rates 
based on diagnoses in pregnant women and the first 12 months of the baby’s life will, 
therefore, be an underestimate of true incidence. Accurate assessment of incidence of CHD 
is important in determining the etiology of CHD, and in comparisons between populations 
over time, which might reflect population genetics or environment factors to a region or 
country. The incidence of CHD ranges from 4 to 85.9 per 1,000 pregnancies. Many 
congenital heart defects have been detected in stillbirths, particularly by an early loss in 
gestation due to chromosome anomalies. According to Hoffman (1978), the incidence of 
CHD among stillbirths is 79 per 1,000, whereas Mitchell (1972) reported an incidence of 
CHD in stillbirths and neonatal death (death after birth and before 28 days of age) to be 27.5 
per 1,000 and 73.2 per 1,000, respectively. Yet, this number is likely an underestimate to the 
actual incidence of CHD because of difficulties in definition and unrecognized live births. 
The increasing incidence of CHD is primarily because of better methods of detection and data 
collection, as well as more advanced instruments, i.e. echocardiography, and highly skilled 
health officers. The increasing incidence of CHD could be due to more teratogenic 
environments affecting pregnant women and their offspring. Although an increased use of 
fetal echocardiography in pregnant women can help detect more CHD cases, many 
pregnancies are aborted prior to the mothers’ awareness of the pregnancy and the effective 
assessment of a structural heart defect is still impossible for the early gestation phase. 
Moreover, the detection of heart malformation via fetal autopsy and heart examination 
remains rarely performed among the stillborns especially in developing country due to the 
lack of pathologists and the additional process for health professionals to request an autopsy.  
2.2 Birth prevalence  
Unlike incidence, the prevalence for CHD is the number of existing cases in the population 
of interest at one point in time. Prevalence represents the probability that a person in a given 
population will have the disease at a given time. Prevalence is a function of the incidence of 
the disease in a population and the duration of that disease. The sooner the recognition of 
birth prevalence of CHD, the better the planning will be by hospitals, health officers, 
pediatricians, pediatric cardiologists and pediatric cardiac surgeons. Social and economic 
support can also be found early for the patients’ families. The global prevalence of CHD 
among newborns ranges from approximately 3.7 to 17.5 per 1,000, which account for 30-45% 
of all congenital defects. In Northern England, birth prevalence of CHD was as high as 79.7 
per 1,000 live births (Dadvand et al., 2008). The extreme variation of the birth prevalence 
might be owed to a single or a combination of the following factors: inclusion criteria, for 
example that reports include bicuspid aortic valve and tiny muscular VSD or not, specificity 
and sensitivity of the diagnostic methodologies, properly trained and technique specialty of 
examiners, and ethnic and regional backgrounds of the examinees. Additional factors might 
be associated with the unavoidable limits of the retrospective studies that the data depend 
on previous medical records, possibly incorrect registration, missing or insufficient co-
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ordination of cardiac pediatricians between outpatient and private clinics, and absence of 
autopsy to determine the cause of certain fetal death in stillbirths. Nonetheless, the 
estimation for birth prevalence of CHD remains simpler and more precise compared with 
the estimation for incidence of CHD from the baby population. Hence, most epidemiological 
studies report the birth prevalence rather than the baby incidence of CHD. Table 1 compares 
the birth prevalence of all CHD subtypes from 4 recent studies by Hoffman & Kaplan, 2002 
(review literatures); Reller et al., 2008 (Metropolian Atlanta Congenital Defects Program, 
MACDP); Dolk & Loane, 2009 (European Surveillance of Congenital Anomalies, Eurocat) 
and Wu et al., 2010 (Asian population, Taiwan). Table 2 shows different percent distribution 














     
VSD 3.57 / 2.83 4.18 3.06 4.01 
PDA  0.80 / 0.57 0.29 --- 2.01 
ASD 0.94 / 0.56 1.31 2.05 3.23 
AVSD 0.35 / 0.34 0.41 0.19 0.20 
PA 0.13 / 0.08 0.04 0.09 --- 
PS  0.73 / 0.53 0.55 0.40 1.22 
AS  0.40 / 0.26 0.11 0.14 0.16 
Coarc  0.41 / 0.36 0.44 0.34 0.25 
TOF  0.42 / 0.36 0.47 0.28 0.63 
TGA  0.32 / 0.30 0.23 0.35 0.21 
HRH  0.22 / 0.16 --- 0.04 --- 
HLH  0.27 / 0.27 0.23 0.26 0.06 
TA  0.08 / 0.09 0.05 0.08 0.05 
Ebstein’s 0.11 / 0.04 0.06 0.05 0.05 
Truncus  0.11 / 0.09 0.06 0.09 0.08 
DORV 0.16 / 0.13 --- --- 0.15 
SV  0.11 / 0.09 0.10 0.07 --- 
TAPVR  0.09 / 0.09 0.08 0.05 0.11 
All CHD  9.60 / 7.67*** 8.14 7.05 13.08 
BAV  13.56/9.24 --- --- --- 
*Live births 
**Non-chromosomal CHD prevalence (Includes: Live birth, Fetal death and Termination of pregnancy 
for fetal anomaly) 
***Excluding bicuspid non-stenosis aortic valves, isolated partial anomalous pulmonary venous 
connection and silent ductus arteriosus 
Table 1. Prevalence of CHD based on CHD subtypes and per 1,000 births compared among 
the four recent studies. 
More importantly, the trend for birth prevalence of CHD was found to be increasing, 
highlighting three chief concerns. First, the increased number of CHD prevalence among the 
newborns could represent the greater number of adults with CHD and the likely increased 
number of CHD in their offspring in the future. This poses the concern about the overall 
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increasing prevalence of CHD. A study in Hungary, estimates the prevalence of CHD to be 
4.9% in offspring of individuals with CHD. More than half of these had the same 
malformation as the parent (Ceizel et al., 1981). Another study in 2001 showed the 
prevalence of CHD was 3.1% in offspring of individuals with CHDs and 1.3% in offspring of 
individuals without CHDs. The adjusted risk for offspring of parents with CHDs was 1.73 
(95% CI, p=0.02) (Romano-Zelekha et al., 2001). On the other hand, if the high prevalence is 
due to the more common use of postnatal echocardiography for abnormal heart diagnosis, 
the greater birth prevalence of CHD signifies an underestimation of CHD among live births 
in the past and the importance for public health officers to have an accurate number of 
cases.  For instance, fetal echocardiography screening could be performed to decide 
pregnancy termination of fetuses with severe cardiac malformation, and thereby reduce the 
birth prevalence of CHD. Finally, the rapid development of the world may increase many 
risk factors to develop CHD such as pollutants and teratogens. The number of births with 
CHD in Dallas county suggests an apparent increase in prevalence from approximately 5% 
in 1971 to 8% in 1984 (Fixler et al., 1990). Within the Baltimore-Washington Infant Study 
Group, the prevalence of CHD increased from 2.8 per 1,000 live births in 1981 to 4.3 per 
1,000 live births in 1988 (Ferencz et al., 1989) and a recent report from North England 
demonstrated the total prevalence of CHD increased from 5.4 per 1,000 births and 
terminations of pregnancy in 1985 to 11.6 per 1,000 births and terminations of pregnancy in 
2003 (Dadvand et al., 2008).   
 
 
1Mitchell et al., 1971, 2Bound & Logan, 1977, 3Dickinson et al., 1981, 4Ferncz et al., 1985, 5Khalil et al., 
1994, 6Alabdulgader, 2006, 7Amro, 2009, 8 Fatema et al., 2008, 9Lindinger et al., 2010 
*Saudi = Saudi Arabia, and Bangla = Bangladesh 
Table 2. Percent distribution of CHD lesions in live births in USA, UK, India, Saudi Arabia, 
Jordan, Bangladesh and Germany. 
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2.3 Adult prevalence 
Similar to the knowledge of birth prevalence, the knowledge of adult prevalence can 
estimate the need for adult cardiology services. The accurate prevalence of CHD in the adult 
population is difficult to know. Although some patients with CHD have spontaneous 
recovery, for instance 35% of infants with VSD had their lesion close spontaneously 
(Mitchell et al., 1971), an overall number of adult diagnosed with CHD continues to rise and 
is now higher than that of the diagnosed pediatric cases. It was estimated that in 2000 there 
were fewer than 150,000 adults diagnosed with CHD in the UK. Of these, around 11,500 had 
the more complex forms of the disease, requiring life-long expert supervision and 
intervention (Report of the British Cardiac Society Working Party, 2002). It was also further 
estimated that by the year 2010 there would be over 185,000 adults in the UK living with 
CHD (over 17,000 with the complex form), a rise of around 25% in simple and 50% in 
complex conditions since 2000. Using a birth prevalence of CHD of 8.8 per 1,000 live births, 
it is estimated that more than 8,500 individuals with surgical repair of congenital heart 
defects reach adulthood each year in the USA (Morris, 2004). In year 2000, approximately 
500,000 American adults were reported to have moderate to complex congenital heart 
defects. By 2020, nearly 760,000 adults will have CHD in the USA, with 200,000 having 
severe CHD, disregarding all those born before 1990 (Webb et al., 2002).  Our review has 
only one study that reports exactly the adult prevalence of CHD. This study was done in a 
general population from 1985 to 2000 in Canada, it revealed the prevalence of CHD was 4.09 
per 1,000 adults for all CHD and 0.38 per 1,000 for those with severe lesions (Table3). 57% of 
the adult CHD population was female (Marelli et al., 2007).  The authors extrapolated a 
prevalence of 4.09 per 1,000 to a Canadian and US population corresponds to 96,000 patients 
in Canada and 856,000 patients in the United States. A recent study in the Netherlands 
studied 8,595 adults with CHD, and found the most common defects in the distribution of 
CHD were ASD (17%), VSD (16%), AS/BAV (14%), TOF (10%) and Coarc (10%) but the 
highest mortality was found in patients with TA (14.7%) and patients with UV and double 
inlet left ventricle (11.4%)(Zomer et al., 2010). 
Two main reasons can explain this situation. First, there is the process of natural selection in 
which children with previously undetected CHD or children with inoperable CHD survive 
into adulthood with uncorrected lesions. Up to 75%of children with CHD did not exhibit 
clinical signs of diseases until the diseases became severe. Moreover, around 10% of CHD 
are not diagnosed until adulthood (Mettler & Peeler, 2009), in particular secundum atrial 
septum defect, ventricular septal defect, pulmonary stenosis, anormalous coronary arteries, 
Ebstein’s anomaly and congenitally corrected transposition of great arteries. One of the 
more recent CHD studies in Thailand reported 0.41 to 1.05 prevalent cases of unrecognized 
CHD for every 1,000 elementary-age students. This variation was due to the topography and 
the limitation of medical staff and facilities in the study areas. In this population, the most 
frequently identified heart defects were VSD 41.4%, PS 16.1%, PDA 12.6% and ASD 9.2% 
(Sayasathid, et al., 2010). The second reason is the improvement of surgical therapy and 
postoperative care of neonates and infants in the past few decades, this has led to increased 
survival of children with CHD. Currently, more than 90% of children born with CHD can 
survive into adulthood (Moons et al., 2009). From 1979 through 1997, mortality associated 
with CHD (all ages) declined 39% from 2.5 to 1.5 per 100,000 (Boneva et al., 2001).  Although 
many children with CHD cannot be cured, the initial therapy, including corrective and 
palliative, allows the adult prevalence of CHD to continue to increase. At Mayo clinic, the 
number of adult patients with CHD who undergo operation has grown to approximately 
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300-400 patients per year (Brown et al., 2009). These patients have elevated risk of premature 
morbidity and mortality. CHD is often more severe and has more complicated treatment in 
adults than children. Moreover, a recent analysis of the United States administrative database 
found that mortality was greater for adults with CHD when the operations were performed by 
adult cardiac surgeons, compared with pediatric (congenital-trained) heart surgeons (4.8% 
versus 1.9%, P<0.001) (Brown et al., 2009, as cited in Karamalou et al., 2008). For CHD adults, 
arrhythmias are more common, cardiac chambers often enlarge, and ventricles tend to develop 
systolic dysfunction. The main causes of death were progressive heart failure 26% and sudden 
cardiac arrest 22% (Zomer et al., 2010). Multidisciplinary care may also be required.  
 
Lesion prevalence per 1,000 adults 
 
Severe lesion 
 TOF or truncus   0.17 
 AVSD    0.14 
 TGA    0.04 
 SV    0.03 
 All severe lesions   0.38 
 
Other lesion 
 ASD    0.88 
 VSD    0.78 
 PDA    0.02 
 AS or AR   0.11 
 Coarc    0.07 
 Ebstein’s   0.01 
 All other lesions   3.71 
All CHD    4.09 
Table 3. The prevalence of adult CHD based on subtypes in year 2000, Canada (Marelli et al., 
2007). 
Another problem that should be of concern is the transfer system from pediatric to adult 
health care. Many children with CHD did not follow-up when they were discharged from 
pediatric care and referred to adult care. In a Canadian study, only 47% of teenagers with 
CHD had transferred successfully to adult care (Reid et al., 2004). The results were similar in 
a German study, 76% of patients with CHD did not have follow-up care as an adult in a 5-
year period (Wacker et al., 2005). The prevalence of adults with CHD is underestimated if it 
does not include this group of patients. These patients received medical care again when 
their diseases had progressed and their symptoms had become severe. This lack of care as 
an adult made it difficult to manage the disease and resulted in high morbidity & mortality 
in these patients. Patients with CHD must recognize the necessesity of ongoing surveillance 
and the transfer system must be developed to prevent the loss of follow-up patients. 
3. Etiology of congenital heart diseases 
The heart development, which initiates at embryonic day 15 in vertebrates, comprises an 
organized series of molecular and morphologic events that involve five primary steps: (1) 
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migration of pre-cardiac cells from the primitive streak and assembly of the paired cardiac 
crescents at the myocardial plate, (2) coalescence of the cardiac crescents to form the 
primitive heart tube, establishment of the definitive heart, (3) cardiac looping, assurance of 
proper alignment of the future cardiac chambers, (4) septation and heart chamber formation, 
and (5) development of the cardiac conduction system and coronary vasculature (McFadden 
& Olson, 2002; Moorman & Christoffels, 2003; Gittenberger-de Groot et al., 2005). From a 
series of complex processes, each component occurs at the right time under the orchestration 
of a cascade of genes and gene products, resulting in the coordination of cell migration and 
the formation of the extracellular matrix. Thus, CHD is usually caused by altered 
development of embryonic structure, or a failure of the structure to develop beyond an early 
embryonic or fetal stage. The anatomical defect generally influences further structural and 
functional development. Although descriptions of abnormal heart development in fetuses 
and babies have remained unclearly defined, substantial knowledge about the etiology of 
CHD have been made during the last decade. Some malformations may be directly inherited 
through vertical gene transfer, underlying the individuals’ genetic disorder, or be associated 
with the consequences of an environmental toxin or diet. Alternatively, random errors in 
cell migration leading to improper cardiac development are possible. Together, the findings 
emphasize the complex and multifactorial causes of the CHD where additional research 
remain needed.  
Better understanding for the etiology and risk factors of CHD is important, and will help 
pave the way for proper preventative measures and treatment guidelines by physicians as 
well as public health officers. The followings represent all reported potential causes of CHD 
to date. 
3.1 Genetic disorders 
The human genome, which contains approximately 20,000 to 25,000 genes, is comprised of 
coding and non-coding regions that are essential for proper protein structure and 
expression. The coding DNA sequence determines the amino acid sequence and 
subsequently the protein structure, and structure determines function (Lander, 2011; Reid-
Lombardo & Bartelings, 2010). The non-coding sequences may contain promoters and 
regulation of transcription. In general, the DNA sequences remain relatively unchanged 
during vertical genetic transfer to the offspring. Nonetheless, occasional changes in the 
nucleotide sequences, referred to as mutations, and horizontal gene transfer do occur. 
Mutations range from a single nucleotide substitution, also called single nucleotide 
polymorphism (SNP), to a deletion or insertion of a DNA fragment. Some mutations only 
appear visible at the level of the chromosome (chromosome abnormalities), while some 
mutations cause phenotypic changes and a heritable trait to the offspring.  
Any change in the DNA sequence, including SNPs, insertion, deletion and shuffling of DNA 
fragment, that results in frameshift mutation of the gene-encoding sequence likely affects 
protein folding and protein function. Abnormal protein folding structure and function can 
cause an improper development of many organs, including the heart. Hence, genetics is 
responsible for one major role in cardiovascular malformation, and indeed the genetic 
disorders represent the most common cause of CHD. Certain chromosome abnormities were 
linked to specific types of congenital heart lesions, and several types have been reported to 
be associated with specific gene defects. For instances, AVSD are often diagnosed in patients 
with trisomy 21.  
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Moreover, CHD that occur in multiple members of a family increases the incidence of CHD 
in familial lines, and support evidences of inherited genetic disorders towards the heart 
abnormities. Molecular genetics in conjunction with cytogenetics provide an opportunity to 
decipher the genetic basis and pathogenesis of CHD. With the rapid era of DNA sequencing 
and genetic discoveries, it is expected that genetic diagnosis and screening will become 
incorporated into standard practice in the near future. Consequently, it is imperative that 
cardiologists understand the basis for genetic disorders, and the medical and ethical 
implications relevant to the genetic information. Today, genetics are predisposed to 
malformation of the hearts and blood vessels, and account for the highest number of human 
birth defects. Thus, hereditary and congenital diseases are classified into three broad 
categories 
3.1.1 Chromosome defect  
Defects in chromosomes associated with CHD are diverse; some examples are aneuploidy or 
polyploidy, improper rearrangement during mitosis and meiosis, translocation, inversion or 
deletions. Importantly, certain chromosomes were reported to have a greater degree of 
significance and of percentages to heart development, and thus the same defects in different 
chromosomes may not result in similar defects (Table 4). About 0.30-2.0% of all live births 
have chromosomal defects, usually the chromosomal defects were aneuploidy and trisomy 
21, 18, 13 (Dolk et al., 2010). Among all CHDs detected during infant period, the 
chromosomal defects account for approximately 6 - 10% (Ferencz et al., 1989; Tennstedt et 
al., 1999; Zhang et al., 2010). In Table 4, defects in chromosomes X, 3, 4, 5, 7, 8, 9, 10, 11, 13, 
17, 18, 21 and 22 showed association with CHD. 
Nonetheless, the table summarizes the data reported by different studies, some conducted 
in different times and places. The incidence of CHD generally depends on multiple factors 
besides the type of genetic disorders and the chromosome where the disorders take place. 
The other factors include how many fetuses are conceived by the mothers, and how many 
of these fetuses reach term alive. Further, the affected number of fetuses also depends on 
the rate of the survival of the affected fetuses and the increased use of therapeutic 
abortion.  
3.1.2 Single gene disorder 
Heart development is controlled by multiple genes regulating a complicated network of 
transcription regulation, translation regulation, and signal transduction pathways, ranging 
from a control of muscle growth, patterning to contractility, to name a few. However, 
mutations in only one or a few components of the cardiac gene network can result in the 
improper development of the heart. One type of heart defect could also be caused by 
different types of single gene disorders. Since the 1990s, researchers have identified more 
than 10 different single gene mutations that can lead to heart defects. To date, many genes 
responsible for several congenital heart defects have been identified (table 5). 
Transcription Factor Genes transcribe and translate proteins that serve to interact 
cooperatively with each other to control gene expression. 
 NKX2-5, the NK family, on chromosome 5q35; Homeobox-containing genes play 
critical roles in regulating tissue-specific gene expression essential for specification of 
heart muscle progenitors (Komuro & Izumo, 1993; Toko et al., 2002). Mutations in 
NKX2-5 result in loss of heart formation in the embryo and have been found in sporadic 
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CCVM. Although the contributions of these variants to the disease phenotype remains 
uncertain, the linkage between this gene disorder and the atrioventricular conduction 
defect, ASD, VSD or TOF, have been found (Elliott et al., 2003; McElhinney et al., 2003; 
Stallmeyer et al., 2010). 
 TBX1, T-box 1 transcription factor, the T-box family; The human TBX1 gene encodes 
another T-box transcription factor, expressed in neural crest and the developing cardiac 
outflow tract (conotruncus) (Calmont et al., 2009). Microdeletion TBX1 gene, located on 
chromosomal 22q11, causes DiGeorge syndrome, also known as Velocardiofacial 
syndrome. There are variable ranges of clinical phenotypes for DiGeorge syndrome, 
including IAA, truncus arteriosus, TOF, DORV and TGA (Jerome & Papaioannou, 2001; 
Xu et al., 2004; Yagi et al., 2003). 
 TBX5, T-box 5 transcription factor, the T-box family; is a member of a phylogenetically 
conserved family of genes that share a common DNA-binding domain, the T-box. TBX5 
was found expressed in embryonic human heart and limb. Mutations in this gene have 
been associated with Holt-Oram syndrome (Fan et al., 2003), which is characterized by 
skeletal malformations of the upper extremities and CHD, most commonly secundum 
ASD but also VSD and TOF (Basson et al., 1999; Faria et al., 2008; Li et al., 1997; Xin et 
al., 2009). 
  GATA4, GATA binding protein 4; is related to zinc finger transcription factors. This 
protein is thought to regulate genes involved in embryogenesis and in myocardial 
differentiation and function. Furthermore, GATA4 interacts with Tbx5 and with Nkx2-5 
to regulate cardiac gene expression. This provides evidence that a transcriptional 
complex including all three proteins may be necessary for proper septation of the 
human heart. Mutations in this gene have been associated with non-syndromic CHD 
cardiac septal defects (Gang et al., 2003; Tomita-Mitchell et al., 2007). 
 TFAP2B, transcription factor AP-2 beta; This gene encodes a member of the AP-2 
family of transcription factors. This protein functions in the differentiation of neural 
crest cell derivatives, and contributes to the embryogenesis of the ductus arteriosus 
(Hilger-Eversheim et al., 2000). Mutations in this gene result in autosomal dominant 
Char syndrome, a dominant disorder comprised of facial dysmorphism, hand 
anomalies, and patent ductus arteriosus (Mani et al., 2005; Satoda et al., 2000; Zhao et 
al., 2001).     
 ZFPM2/FOG2, zinc finger protein, multitype 2; The zinc finger protein encoded by 
this gene is a widely expressed member of the FOG family of transcription factors. 
The FOG family members modulate the activity of co-factors with the GATA family 
of proteins, which are important regulators of hematopoiesis and cardiogenesis in 
mammals. In experimental gene targeting of ZFPM2/FOG2 in mice, the mutation 
resulted in cardiac malformation including TOF, endothelial specific disruption 
(DORV, a common AV valve), VSD and ASD as well as left ventricular wall 
hypoplasia, and the failure to form coronary arteries (Tevosian et al., 2000). Recent 
reports found mutations of the ZFPM2/FOG2 gene associated with TOF (De Luca et 
al., 2010; Pizzuti et al., 2003). 
 ZIC3, Zic family member 3 heterotaxy 1; This gene encodes a member of the ZIC 
family of C2H2- type zinc finger proteins. Mutations in ZIC3 gene, located at 
chromosome Xq24-q27.1 (Casey et al., 1993), cause X-linked visceral heterotaxy and 
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complex CHD including ASD, AVSD, TGA, PS, and TAPVR (Zhu et al., 2007; Grinberg 
& Millen, 2005).  
Cell signaling genes produce proteins involved in cell signal transduction, which allow 
cells to respond to their environment and are therefore involved in regulation of many 
important biological functions. 
 JAG1, Jagged 1; The jagged 1 protein encoded by JAG1 is the human homolog of the 
Drosophila jagged protein. Human jagged 1 is the ligand for the receptor NOTCH, 
which is essential in many organ developmental programs. Analysis of JAG1 
expression during mammalian embryogenesis showed its high level of gene expression 
during the heart and vessel developing periods, and the finding was consistent with the 
crucial role of its patterning of the right heart and pulmonary vasculature (Loomes et 
al., 1999). Mutations in the jagged 1 protein cause Alagille syndrome, a complex disease 
characterized by liver problem, PS, and with or without TOF (Heritage et al., 2002; 
McElhinney et al., 2002; Colliton et al., 2001).  
 NOTCH1, NOTCH2, The NOTCH family receptors; The NOTCH gene encodes a 
single-pass transmembrane protein receptor that interacts with the ligands named Delta 
and Serrate/Jagged, and perform many cellular regulatory function. Mutations in 
NOTCH1 have been shown to cause autosomal-dominant aortic valve defects, and 
bicuspid (two-leaflet) aortic valve (Grag et al., 2005; McKellar et al., 2007; Mohamed et 
al., 2006). Because BAV is a risk factor for valve calcification, it has previously been 
hypothesized that calcification was due to increased blood flow turbulence across the 
valve leaflets (Robicsek et al., 2004), leading to progressive aortic stenosis and 
regurgitation in later life. Furthermore, mutation in NOTCH2 receptor was recently 
found to be able to cause Alagille syndrome even in the patients with no Jagged1 
mutations (El-Rassy et al., 2008; McDaniell et al., 2006). 
 PTPN11; The protein encoded by this gene is a member of the protein tyrosine 
phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a 
variety of cellular processes including cell growth, differentiation, mitotic cycle, and 
oncogenic transformation. Mutations in this gene are a cause of Noonan syndrome, 
located on chromosome 12q24 (Jamieson et al., 1994), it is an autosomal dominant 
disorder characterized by dysmorphic facial features, skeletal malformations, short 
stature, and cardiac abnormalities, most characteristic are PS, ASD, AVSD and 
hypertrophic cardiomyopathy (Jongmans et al., 2005; Sarkozy et al., 2003). 
 CFC1, cryptic family 1; This gene encodes a member of the EGF-Cripto, Frl-1, and 
Cryptic (CFC) family. These proteins play key roles in intercellular signaling 
pathways during vertebrate embryogenesis. This protein is involved in left-right 
asymmetric morphogenesis during organ development. Mutations in this gene can 
cause autosomal visceral heterotaxy with complex CHD including TGA, septal 
defects and systemic vein anomalies (Goldmuntz et al., 2002; Ozcelik et al., 2006; Yan 
et al., 1999). 
 SOS1, son of sevenless homolog 1; This gene encodes a protein that is a guanine 
nucleotide exchange factor for RAS proteins, membrane proteins that bind guanine 
nucleotides and participate in signal transduction pathways. Mutations in this gene are 
associated with gingival fibromatosis 1 and Noonan syndrome (Serrano-Martin et al., 
2008). 
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 PROSIT240, also known as THRAP2; An evolutionarily conserved THRAP genes 
encode a family of proteins that regulate embryonic development. Missense mutation 
PROSIT240 gene has been identified as a cause of transposition of the great arteries 
(Muncke et al., 2003). 
 CRELD1, cysteine-rich with EGF-like domains 1; CRELD1 is the member of a family 
of matrix cellular proteins. Matrix cellular proteins contain epidermal growth factor-like 
repeats, and are grouped in a class of cysteine-rich domains that mediate interactions 
between proteins of diverse functions. Mutation in CRELD1 genes, locating on 
chromosome 3p25 locus, represents a vital gene position for AVSD (Guo et al., 2010; 
Zatyka et al., 2005; Robinson et al., 2003).   
 EVC, EVC2; This gene encodes a protein containing a leucine zipper and a 
transmembrane domain. The functions of EVC and EVC2, which share a promoter, are 
aligned in control limb, skeleton and teeth development. Mutation of this gene has been 
implicated in both Ellis-van Creveld syndrome and Weyers acrodental dysostosis, the 
disease locus mapped to chromosome 4p16 (Polymeropoulos et al., 1996). Ellis–van 
Creveld syndrome is an autosomal recessive disorder characterized by 
chondrodysplasia and CHD, typically a common atrium of the atrioventricular septal 
defect type or secundum type atrial septal defects (Ali et al., 2010; Hills et al., 2011; 
Tompson et al., 2007). Some heterozygous carriers of these mutations manifested 
Weyers acrodental dysostosis suggesting it is allelic with Ellis–van Creveld syndrome 
(Riiz-Perez et al., 2000). 
 TGFBR1 and TGFBR2, transforming growth factor receptor 1 and 2; This gene 
encodes a member of the Ser/Thr protein kinase family and the TGFB receptor 
subfamily. Mutations in this gene have been associated with Marfan syndrome, Loeys–
Deitz Aortic Aneurysm syndrome (Loeys et al., 2006; Singh et al., 2006). 
Extracellular Matrix Protein Genes encode extracellular matrix proteins which cause 
congenital syndromes involving arteriopathies of different forms. 
 ELN, elastin; This gene encodes a protein is one of the two components of elastic fibers. 
It resides in the Williams critical region on 7q11.23. Deletions and mutations in this 
gene are associated with Williams or Williams-Beuren syndrome in which the 
phenotype is comprised of characteristic endocrine, cognitive, and facial features in 
association with areas of arterial narrowing, most typically non-syndromic 
supravalvular AS (Micale et al., 2010; Rodriguez-Revenga et al., 2005; Arrington et al., 
2006). 
 FBN1, fibrillin 1; This gene encodes a member of the fibrillin family. This fibrillin has 
long been assumed to be critical in the aortic wall and other connective tissues as a 
structural protein. Mutations in this gene are associated with Marfan syndrome 
(Brautbar et al., 2010; De Backer, 2009; Li et al., 2008). Marfan syndrome is an autosomal 
dominant disease of connective tissue principally involving the skeletal, ocular systems 
and cardiovascular malformation whose manifestations include mitral valve prolapse 
and regurgitation, presenting in infancy in the most severe cases, and progressive 
aneurismal dilation of the aortic root with the potential for catastrophic aortic dissection 
and rupture. Marfan syndrome was first mapped to chromosome 15 using traditional 
genetic linkage analysis (Dietz et al., 1991). Other studies have revealed that fibrillin has 
a regulatory role in TGF- signaling, and dysregulation of the pathway may instead 
underlie Marfan pathogenesis (Neptune et al., 2003). 
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ASCA: aberrant subclavian artery, CPVD: congenital polyvalvular disease, CVM: cardiovascular 
malformations, DCM: dilated cardiomyopathy, RAA: right aortic arch, SVAS: supravalvular aortic stenosis 
(Ref: 1Douchin et al., 2000; 2Lichiardopol & Morta, 2004; 3Mazzanti & Cacciari, 1998; 4Poprawski et al., 
2009; 5Tan & Yeo, 2009; 6Lin et al., 2007; 7Lizarraga et al., 1991; 8Musewe et al., 1990; 9Van Praagh et al., 
1989; 10Matsuka et al., 1981; 11Musewe et al., 1990; 12Paladini et al., 2000; 13Weijerman et al., 2010; 
14Berends et al., 2001; 15Rosias et al., 2001; 16Wilson et al., 1984; 17Akdeniz et al., 2009; 18Barisic et al., 2008; 
19Selicorni et al., 2009; 20Digilio et al., 2003; 21Giltay et al., 1998; 22Roskers et al., 1990; 23Green et al., 2000; 
24Shuib et al., 2009; 25Battaglia et al., 1999; 26Tsai et al., 1999; 27Strehle & Bantock, 2003; 28Huang et al., 
2002; 29Hills et al., 2006; 30Devriendt et al., 1999; 31Wat et al., 2009; 32Lindstrand et al., 2010; 33Van Esch et 
al., 1999; 34Grossfeld et al., 2004; 35Mattina et al., 2009; 36Digilio et al., 2000; 37Movahhedian et al., 1991; 
38Cody et al., 1999; 39Linnandivi et al., 2006; 40Eronen et al., 2002;41Ferrero et al., 2007; 42Edelman et al., 
2007;43Potocki et al., 2003; 44Ballesta et al., 2008; 45Shprintzen, 2008) 
Table 4. Chromosome abnormality associated with congenital heart anomalies and their 
percentages. 
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AD: autosomal dominant, AR: autosomal recessive, AVB: atrioventricular block; HCM: hypertrophic 
cardiomyopathy, HOS: Holt–Oram syndrome, SVAS: supravalvular aortic stenosis 
Table 5. Gene abnormality and contiguous gene syndromes associated with congenital heart 
anomalies. 
3.1.3 Polygenic / Multifactorial inheritance  
Multifactor inheritance, also known as polygeny, relies on the concept of threshold limit, 
when the threshold limit of the combined genetic and environmental factors is reached, 
malformation results. Below the threshold level, the malformation is absent. One common 
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key risk is that the babies are genetically oriented towards some level of atypical 
cardiovascular formation and/or development, together with the exposure to other 
causative factors. Different stages of cardiac development possess various degrees of 
vulnerability to environmental factors. Some clues to multifactorial inheritances are a reason 
for CHD, including a lack of consistent CHD people in the pedigree of the family, and an 
occasional abnormality with no recognizable pattern in the pedigree of the family. 
3.2 Maternal factors  
Various teratogenic agents have been implicated as the etiologic agents of CHD. For 
example, women who have insulin-dependent diabetes mellitus, and those who take certain 
medications, such as acne and epilepsy medication, have a higher risk for having babies 
with CHD. Women with drug or alcohol abuse also have predisposing risks. The basic 
biological principle mechanism of teratogens action that cause CHD include susceptible 
stage of organogenesis development, genetic differences in susceptibility, dose response 
relationships, and specific actions of the teratogenic agent. The highest degree of embryonic 
and fetal sensitivity or susceptibility to adverse effects of exposure to teratogens occurs 
during the first trimester, especially during the 2nd to 8th week of embryonic life. Dose 
response relationship implies that for each teratogen there is a dose threshold, theoretic dose 
below which no adverse effects can be observed. 
3.2.1 Maternal health and medical disease  
Certain chronic illnesses in the mother (table 6), such as diabetes, and other viral infections, 
such as the flu, may contribute to heart defects. 
 Maternal diabetes mellitus; The study by Correa et al. found odds ratios for pre-
gestational diabetes mellitus (PGDM) and all cardiac defects was 4.64 (2.87-7.51), while 
gestational diabetes mellitus (GDM) was associated with cardiac defects found 1.59 
(1.27-1.99) (Correa et al., 2008). This excess risk is related to the level of maternal 
hyperglycemia during the embryonic period. The overall risk of one or more major 
anomalies is 6 to 7 percent, which is double the risk in the general obstetric population 
(Wyatt et al., 2005). Congenital heart defects increased in diabetic pregnancy include 
heterotaxy, TOF, TGA, septal defects, anomalous pulmonary venous return, and 
various defects causing left or right outflow obstruction (Lisowski et al., 2010; Corrigan 
et al., 2003; Wren et al., 2003). The possible mechanism is that embryonic hyperglycemia 
may cause disturbances in metabolism of arachidonic acid, inositol and promote 
excessive formation of oxygen free radicals which causes mitochondrial damage, and 
activation of apoptotic pathways. 
 Maternal phenylketonuria; One of the most common teratogen of pregnancy 
complications, when these pregnancies are untreated, 90% of the offspring suffer 
microcephaly, mental  retardation and increased risk of heart defects through increased 
blood levels of phenylalanine and phenyl pyruvic acid (Rouse & Azen, 2004). 
Frequencies of congenital abnormalities increased with increasing maternal 
phenylalanine levels. The MPKUCS has demonstrated an increased rate of CHD (7.5%), 
the most frequent cardiac defects are TOF, Coarc, PDA, HLH and VSD (Levy et al., 
2001). Diet control before conception and during pregnancy reduces the risk of CHD 
(Matalon et al., 2003; Michals-Matalon et al., 2002).   
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 Maternal connective tissue diseases; Connective tissue disease is a group of multi-
system disorder, such as systemic lupus erythematosus (SLE), which have been 
associated with congenital complete atrioventricular heart block in offspring. With 
regard to maternal anti-Ro and anti-La autoantibodies can transmit from a mother to 
the fetus, which causes a fetal inflammatory response that damages the AV nodal and 
myocardial tissue in susceptible fetus’ which may result in myocarditis, endocardial 
fibroelastosis and cardiac arrhythmias (Buyon et al., 2009; Clancy & Buyon, 2004). 
 Maternal rubella; Women who contract rubella during pregnancy have a high risk of 
having a baby with congenital rubella syndrome (CRS) which will cause effects such as 
miscarriage, stillbirth, and a series of birth defects. The risk of fetal infection varies 
according to the time of onset of maternal infection. Infection rates are highest during 
the first trimester. The most common manifestations of CRS are congenital cataracts, 
sensorineural deafness, and congenital heart defects (especially PDA). When the heart is 
targeted, there is direct viral damage to the myocardium, affecting primarily the left 
atrium and the heart septa, leading to thrombosis, necrosis, and hemorrhage that cause 
of PDA, PS, and ASD (De Santis et al., 2006; Webster, 1998). 
 Maternal febrile illness; Influenza during the first trimester of pregnancy is associated 
with febrile illness, which appears to cause more right-sided obstructive heart defects, 
especially TA and PA, some left obstructive defects and VSD (Oster et al., 2011; 
Tikkanen & Heinonen, 1991; Yu et al., 2008; Botto et al., 2001). In both hyperthermia and 
infection there have been documented biological effects on developmental apoptosis 
pathways. It has been suggested that altered apoptosis may cause birth defects, and 
apoptosis is known to be involved in cardiac morphogenesis, such as in the 
development of the cardiac outflow tract. 
 Maternal Stress; Intense maternal stress during the periconceptional period was 
associated with increased risk of delivering infants with certain congenital anomalies 
particularly with conotruncal heart defects and neural tube defects (Carmichael & 
Shaw, 2000; Adams et al., 1989). 
 Maternal obesity; Many studies have examined the association between maternal 
prepregnancy and during pregnant obesity (elevated BMI >25.0 Kg/m2) with CHD 
such as ASD, VSD, conotruncal defects and right ventricular outflow tract defects 
(Cedergren & Kallen, 2003; Mills et al., 2010; Oddy et al., 2009; Gilboa et al., 2010). 
Several aspects of such potential associations between obesity and heart defects remain 
unclear due to studies of obesity and heart defects which are difficult to assess and 
compare because of the possibility of bias in obesity that may associated with 
unrecognized diabetes. While some literature found no association between maternal 
weight and isolated CHDs (Khalil et al., 2008; Watkins & Botto, 2001). 
3.2.2 Maternal drug and medical use  
Consumption of many drugs, such as thalidomide and isotretinoin, during early 
gestationcan interfere with the normal cardiogenesis of the fetus. This list of definite and 
potential human cardiac teratogens was showed in table 6. 
3.2.3 Maternal drugs abuse 
Some studies suggest that drinking alcohol or using cocaine, especially during the 
pregnancy, can increase the risk of congenital heart defects (table 6). 
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 Caffeine; Caffeine can cross the placenta, and the concern that caffeine may causes birth 
defects prompted the FDA to caution pregnant women to limit their caffeine intake. 
Today, there is no evidence associating caffeine ingestion during pregnancy and 
teratogenicity of congenital heart disease (Pejtsik et al., 1992; Linn et al., 1982). 
 Alcohol; Maternal alcohol use during pregnancy is associated with fetal alcohol 
syndrome which comprise a spectrum of abnormal face, growth restriction, central 
nervous system abnormality and cardiac defects with VSDs  occurring most commonly 
(Pejtsik et al., 1992; Carmichael et al, 2003; Burd et al., 2007; Loser et al., 1992). In Spain, 
a case-control study by Martinez-Frias et al. reported that a higher risk of developing 
CHDs was found in the group with the highest-level daily doses of alcohol 
consumption (the absolute alcohol ingestion was more than 92 gram per day. However, 
mechanism in teratogenic effect of alcohol on the developing heart malformation is as 
of now unclear. 
 Cocaine; Maternal cocaine ingestion was reported to induce coronary thrombosis in the 
developing fetal heart leading to formation of a single ventricle, other defects were also 
reported, such as Ebstein’s anomaly, VSD, heterotaxy (Linn et al., 1982; Kueh & 
Loffredo, 2002; Lipshultz et al., 1991; Martin & Khoury, 1992). 
 Cigarette Smoking; Smoking during pregnancy enhances the risk of adverse pregnancy 
outcomes such as low birth weight. The relationship between gestational smoking and 
congenital heart defects has been studied, however the information is inconclusive. 
Some studies have reported associations between maternal smoking and ASD, AVSD, 
TOF (Alverson et al., 2011; Malik et al., 2008; Kallen, 1999). A recent study in Greece 
found that periconceptional tobacco smoking was associated with increased risk of 
CHD in the offspring (OR=2.7) and has been associated with a quantity of cigarette 
smoking (Karatza et al., 2011).  However, no associations were found (Kallen, 1999) so 
research on large population-based studies is required to evaluate. 
3.3 Environment or lifestyle factors 
Evidence of teratogenic contamination in certain environments and workplaces is sporadic, 
albeit environmental factors are a more common cause for multifactorial inheritance CHD. 
Definitive evidence for the causal relationship between certain exposure and CHD is still 
unavailable. Available evidence suggests the finding of the higher incidence of CHD babies 
from women who reside in area with drinking water contaminated by trichloroethylene, 
dichloroethylene and chromium. While maternal exposure to paint, lacquer, agricultural 
chemicals, organic solvents, dyes and lead have also been occasionally found statistically 
associated with CHD. Ingestion of heavy metals and lifetime accumulation of a considerable 
amount of heavy metals through diet also affects CHD development in babies (table 6). 
 Organic Solvents; A few studies reported increased risk of HLH, Coarc, PS, TGA with 
intact ventricular septum, TOF, TAPVR, non-chromosomal AVSD and Ebstein’s 
anomaly. Other reports of occupational exposure to organic solvents have been 
associated with an increased risk of VSD (Tikkanen & Heinonen, 1991, 1992; Shaw et al., 
2003). However the precise links are difficult to clarify, because solvent composition 
varies between different commercial preparations. 
 Pesticides & Other Toxic Substances; A study by Adam et al suggests an association of 
maternal employment in the agricultural industry with an increased risk of conotruncal 
defects that suggests a possible association with chemicals used in agriculture (Adams  
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(Ref: 1Lisowski et al., 2010; 2Corrigan et al., 2009; 3Wren et al., 2003; 4Rouse & Azen, 2004; 5Buyon et al., 
2009; 6Clancy & Buyon, 2004; 7Row, 1973; 8De Santis et al., 2006; 9Webster, 1998; 10Botto et al., 2001;  
11Carmichael & Shaw, 2000; 12Adam et al., 1989; 13Cedergren & Kallen, 2003; 14Mills et al., 2010; 15Oddy et 
al., 2009; 16Gilboa et al., 2010; 17Cohen et al., 1994; 18Jacobson et al., 1992; 19Rothman et al., 1995; 20Botto et al., 
2001; 21Lammer et al., 1985; 22Willhite et al., 1986; 23Rischbieth, 1979; 24O’Brien & Gilmour-White, 1993; 
25Sonoda et al., 1993; 26Winter et al., 1987; 27Hou, 2004; 28Smithells & Newman, 1992; 29Ericson & Kallen, 
2001; 30Czeizel et al., 2001; 31Newman & Correy, 1983; 32Crider et al., 2009; 33Cooper et al., 2006; 34Kallen & 
Otterblad Olausson, 2006; 35Bar-Oz et al., 2007; 36Berard et al., 2007; 37Pejtsil et al., 1992; 38Carmichael et al., 
2003; 39Burd et al., 2007; 40Loser et al., 1992; 41Alverson et al., 2011; 42Malik et al., 1999; 43Kallen, 1999; 44Linn 
et al., 1982; 45Kuehl & Loffredo, 2002; 46Lipshultz et al., 1991; 47Martin & Khoury, 1992; 48Tikkanen & 
Heinonen, 1991; 49Shaw et al., 2003; 50Tikkanen et al., 1992; 51Gilboa et al., 2005; 52Dadvand et al., 2011) 
Table 6. Risk factors that are known or believed to be associated with the congenital heart defects. 
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et al., 1989). In the Baltimore-Washington Infant Study (BWIS), potential exposure to 
herbicides and rodenticides was associated with an increased risk of TGA, while 
potential exposure to pesticides was associated with TAPVR and VSD. A case-control 
study of various end-product uses reported an increased risk of conotruncal defects 
with maternal reports of exposure to insecticides (Shaw et al., 1999). 
 Air Pollution; Ambient air pollution such carbon monoxide (CO), nitric oxide (NO), 
ozone (O3), and sulfur dioxide (SO2) may cause CHD dependent on pollutant levels 
(Ritz et al., 2002; Rankin et al., 2009). A study by Gilboa et al, observed positive 
associations between carbon monoxide and isolated ASD, TOF, particulate matter < 10 
μm in diameter and isolated ASD as well as between ozone and VSD (Gilboa et al., 
2005). From a study by Dadvand et al, exposure to CO and NO has been associated 
with ventricular septal defect and cardiac septa malformations. CO was also associated 
with congenital pulmonary valve stenosis and NO was associated TOF (Dadvand et al., 
2011). Further studies are also required to clarify if air pollution exposure influences the 
risk for CHD. 
 Maternal Home Tap Water Consumption; It has a positive association between a 
mother's consumption of home tap water during the first trimester of pregnancy and 
cardiac anomalies. This was unrelated to water contamination, mother's race, or her 
educational level (Shaw et al., 1990). 
 Waste Sites; Many of the recent studies about possible increased risk of CHD in 
communities situated near hazardous waste sites are inconsistent (Croen et al., 1997) 
and may not ultimately prove to be causal. 
 Ionizing Radiation; there are few reports on possible associations of CHD with 
maternal exposure to ionizing radiation in occupational settings or as part of medical or 
dental evaluations. Studies found no clear evidence of any association. Further studies 
are also required to clarify the precise relationship between these factors and CHD. 
4. Prevention 
Excluding genetic counseling, the genetic disorder cannot be protected against; simple 
guidelines to pregnant mothers for prevention of CHD in their newborns are good diet, 
physical activity, lifestyle, environments and occupation that the parents should discuss 
with their primary care provider or obstetrician. Women of childbearing age also should 
obtain prenatal care, including testing for diabetes and past rubella immunization, they 
should also discuss any medication use with their obstetrician; and should avoid contact 
with ill people, especially those with rubella or influenza. Women of childbearing age 
should take 400 micrograms of folic acid on a daily basis starting before pregnancy, which 
can reduce congenital heart and neural tube defects, and should avoid certain types of 
behaviors such as exposure to organic solvents, smoking and heavy alcohol use. If a woman 
has no immunity to rubella, she should get vaccinated prior to pregnancy. Preconception 
care and appropriate dietary management for women with phenylketonuria should be an 
important strategy. Detection and appropriate management of diabetes before and during 
pregnancy should be an important step for reducing risk of CHD in offspring. Avoidance of 
medications that are suspected to cause congenital defects, including congenital heart 
disease, should be taken, and the medications should have warnings about that risk to allow 
mothers and physicians to make informed decisions about the risks and benefits of the use 
of the medication during pregnancy. Recommendations also are possible for screening for 
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possible cardiac defects using fetal echocardiography during pregnancy when warranted by 
reports of prenatal maternal illnesses or exposures. The need for screening any individual 
should be made on an individual basis from the type, likelihood, and level of potential 
exposure, as well as the time of gestation during which it occurred. This decision typically 
will be made as a result of the obstetrical history. Because congenital heart defects represent 
some of the more prevalent birth defects, that result in significant lifelong morbidity, and 
are an important cause of mortality attributed to birth defects, the development of effective 
prevention interventions is paramount from a public health perspective. 
5. Conclusion 
The number of patients, both children and adults, with CHD has continued to rise. The most 
common reasons for CHD are associated with multiple factors. Epidemiology studies reveal 
underestimated cases of CHD, and together with the etiology the studies help to define 
potential risk factors for CHD. The epidemiology and etiology of CHD also help prioritize 
the areas needed for intervention and additional regulations the public health officers may 
impose. Patients and parents of babies with CHD must understand the significance of 
routine medical checkups, which can be accomplished though an effective transition 
program and collaboration among healthcare providers.  
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